Evotec AG announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing program, which has entered the lead optimization phase. The program aims to find novel small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
The program was initiated in 2010 with a high-throughput screen followed by extensive hit validation and hit-to-lead activities, leveraging Evotec’s hit identification and integrated medicinal chemistry platforms.
Dr. Mario Polywka, Chief Operating Officer at Evotec stated: “This is an area where Evotec has a significant track record of success and we look forward to leveraging our expertise to assist Active Biotech in finding novel treatments addressing cancer and autoimmune disorders.”
Dorthe da Graca Thrige, Director of Development of Active Biotech, commented: “Active Biotech strives to develop, efficiently and cost-effectively, new remedies for illnesses where today’s treatment options are inadequate, especially in the area of cancer and autoimmune diseases.”
Date: April 26, 2012
Source: Evotec AG
Filed Under: Drug Discovery
